Bausch Health Companies Inc. Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount
Bausch Health Companies Inc. (BHC) reported Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-01.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxExemptIncome · last filed 2017-03-01
- Bausch Health Companies Inc. effective income tax rate reconciliation, tax exempt income, amount for fiscal 2016 was $0.00.
- Bausch Health Companies Inc. effective income tax rate reconciliation, tax exempt income, amount for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- Bausch Health Companies Inc. effective income tax rate reconciliation, tax exempt income, amount for fiscal 2014 was $50.00M.
- Bausch Health Companies Inc. effective income tax rate reconciliation, tax exempt income, amount for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
| Period end | Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount 12 month as first filed |
|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-01 | |
| 2015-12-31 | $0.00 10-K · filed 2017-03-01 | |
| 2014-12-31 | $50.00M 10-K · filed 2017-03-01 | $50.10M 10-K · filed 2015-02-25 |
| 2013-12-31 | $0.00 10-K · filed 2016-04-29 | |
| 2012-12-31 | $3.10M 10-K · filed 2015-02-25 | $3.06M 10-K · filed 2013-02-28 |
| 2011-12-31 | $15.38M 10-K · filed 2014-02-28 | |
| 2010-12-31 | $1.68M 10-K · filed 2013-02-28 | |
| 2009-12-31 | $3.84M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |